GRAL vs CRL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRL Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Charles River Laboratories International, Inc. (CRL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GRAL counters with relative strength in Valuation. Fundamentally, GRAL trades at 1.1x Forward P/E with -332.0% operating margin (+3.7% YoY revenue) versus CRL at 25.9x Forward P/E and 14.3% operating margin (-2.2% YoY). In options structure, GRAL sits in BREAKDOWN (53rd %ile IV; Dealer Gamma Walls on Pro) against CRL sits in UNCLASSIFIED (11th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GRAL | CRL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.2B | $16.2B | Larger Scale | CRL |
| Trailing P/E Ratio Valuation | 1.1x | N/M | Lower Multiple | GRAL |
| Forward P/E Ratio Valuation | 1.1x | 25.9x | Lower Multiple | GRAL |
| Revenue Growth (YoY) Growth | +3.7% | -2.2% | Higher Growth | GRAL |
| Operating Margin (TTM) Profitability | -332.0% | 14.3% | Higher Margin | CRL |
| Net Profit Margin Profitability | -243.8% | 1.0% | Higher Margin | CRL |
| Return on Equity (ROE) Capital Efficiency | -17.3% | 1.3% | Higher ROE | CRL |
| 52-Week Range Position Momentum | 51% ($42โ$166) | 81% ($146โ$380) | Stronger Trend | CRL |
| Beta / 30D Volatility Risk Regime | 3.09ฮฒ ยท 99% Vol | 1.09ฮฒ ยท 68% Vol | Lower Realized Risk | CRL |
| Unified Institutional Score Composite Signal | 54.5 / 100 (HOLD) | 48.0 / 100 (HOLD) | Higher Composite | GRAL |